People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology, AI / ML, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gameto, Inc. | — | Biotechnology | Series C | $123.6M | $262.4M | 2021 |
| Unlearn.ai, Inc. | — | AI / ML | Series C | $115.0M | $592.7M | 2024 |
| Averna Therapeutics Inc. | — | Pharma | Series C | $85.0M | $805.0M | 2024 |
| Superluminal Medicines, Inc. | — | Biotechnology | Series B | $50.7M | $22.0M | 2023 |
| Switch Therapeutics Inc. | — | Pharma | Series B | $23.3M | $326.3M | 2022 |
| Capacity Bio, Inc. | — | Pharmaceuticals | Series B | $19.2M | $245.7M | 2022 |
| Profluent Bio Inc. | — | Biotechnology | Series A | $8.0M | $103.3M | 2022 |
| Deciduous Therapeutics, Inc. | — | Biotechnology | Series A | $5.8M | $211.3M | 2019 |
Dylan Morris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dylan Morris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Kevin Zhang | 1 | 11 |
| Stephen Squinto | 1 | 8 |
| Henry Chen | 1 | 7 |
| Francisco Gimenez | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Amy Wang | 1 | 5 |
| Maryanna Saenko | 1 | 4 |
| Richard Morris | 1 | 4 |
| Eric Shiozaki | 1 | 4 |
| Taro Inaba | 1 | 4 |
| Charles Fisher | 1 | 4 |
| Tal Zaks | 1 | 3 |
| John McGovern | 1 | 3 |
| Aaron Smith | 1 | 3 |
| Nick Olsen | 1 | 2 |
| CONY D'CRUZ | 1 | 2 |
| Jonathan Hostens | 1 | 2 |
| Dusan Perovic | 1 | 2 |
| DIAMANTIS XYLAS | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.